Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n = 647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study

European Journal of Cancer

Volumn 45, Issue 14, 2009, Pages 2528-2536

  Willemoe, Gro L ^a   Hertel, Pernille B ^a,b   Bartels, Annette ^b   Jensen, Maj Britt ^c   Balslev, Eva ^d   Rasmussen, Birgitte B ^d   Mouridsen, Henning ^a,c   Ejlertsen, Bent ^a,c   Brünner, Nils ^b  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Danish Breast Cancer Cooperative Group   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Anthracyclines; Breast cancer; Resistance; TIMP 1

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR CELL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DENMARK; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASM PROTEINS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TREATMENT OUTCOME;

EID: 69249142934     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.05.029     Document Type: Article

References (28)

1. Mouridsen H.T. New cytotoxic drugs in treatment of breast cancer. Acta Oncol 29 (1990) 343-347
2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
3. Gennari A., Sormani M.P., Pronzato P., et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst 100 (2008) 14-20
4. Dhesy-Thind B., Pritchard K.I., Messersmith H., et al. HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat 109 (2008) 209-229
5. Knoop A.S., Knudsen H., Balslev E., et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 23 (2005) 7483-7490
6. Pritchard K.I., Messersmith H., Elavathil L., et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26 (2008) 736-744
7. Di Leo A., Dowsett M., Horten B., and Penault-Llorca F. Current status of HER2 testing. Oncology 63 Suppl 1 (2002) 25-32
8. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25 (2007) 5287-5312
9. Goldhirsch A., Wood W.C., Gelber R.D., et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 8 (2007) 1133-1144
10. Schrohl A.S., Meijer-van Gelder M.E., Holten-Andersen M.N., et al. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 12 (2006) 7054-7058
11. Davidsen M.L., Wurtz S.O., Romer M.U., et al. TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis. Brit J Cancer 95 (2006) 1114-1120
12. Wurtz S.O., Schrohl A.S., Sorensen N.M., et al. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 12 (2005) 215-227
13. Jung K.K., Liu X.W., Chirco R., Fridman R., and Kim H.R. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 25 (2006) 3934-3942
14. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008;1:re6.
15. McShane L.M., Altman D.G., Sauerbrei W., et al. Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23 36 (2005) 9067-9072
16. Ejlertsen B., Mouridsen H.T., Jensen M.B., et al. Improved outcome from substituting methotrexate with epirubicin: results from a randomised comparison of CMF versus CEF in patients with primary breast cancer. Eur J Cancer 43 (2007) 877-884
17. Moller S., Jensen M.B., Ejlertsen B., et al. The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG): its 30-years experience and future promise. Acta Oncol 47 (2008) 506-524
18. Elston C.W., and Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19 (1991) 403-410
19. Andersen J., Thorpe S.M., King W.J., et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 26 (1990) 442-449
20. Henriksen K.L., Rasmussen B.B., Lykkesfeldt A.E., et al. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 60 (2007) 397-404
21. Sorensen I.V., Fenger C., Winther H., et al. Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue. J Histochem Cytochem 54 (2006) 1075-1086
22. Schemper M., and Smith T.L. A note on quantifying follow-up in studies of failure time. Control Clin Trials 17 (1996) 343-346
23. Hudis C.A., Barlow W.E., Costantino J.P., et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25 (2007) 2127-2132
24. Sorensen N.M., Dowell B.L., Stewart K.D., et al. Establishment and characterization of 7 new monoclonal antibodies to tissue inhibitor of metalloproteinases -1. Tumor Biol 26 (2005) 71-80
25. Li G., Fridman R., and Kim H.R. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 59 (1999) 6267-6275
26. Liu X.W., Bernardo M.M., Fridman R., and Kim H.R. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 278 (2003) 40364-40372
27. Schrohl A.S., Pedersen A.N., Jensen V., et al. Tumor tissue concentrations of the proteinase inhibitors TIMP-1 and PAI-1 are complementary in determining prognosis in primary breast cancer. Mol Cell Proteom 3 (2003) 164-172
28. Schrohl A.S., Holten-Andersen M.N., Peters H.A., et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 10 (2004) 2289-2298